EBV BRLF1 28-37 (HLA-A*24:02) DYCNVLNKEF

The EBV BRLF-1 148–156 peptide (RVRAYTYSK) is a well-characterized CD8+ T-cell epitope derived from the Replication and Transcription Activator (RTA / BRLF-1; UniProt: P03209; epitope ID: 56390) of Epstein-Barr Virus (EBV / Human Herpesvirus 4). As an immediate-early lytic cycle protein, BRLF-1 triggers the viral reactivation cascade, making this nonamer peptide a primary target for assessing lytic-phase CD8+ T-cell responses. Restricted by HLA-A*03:01 and HLA-A*11:01, RVRAYTYSK is an essential component in standardized recall panels and routine human T-cell immunomonitoring.Key Features & BenefitsHLA-A*03:01 & HLA-A*11:01 Restriction: Specific anchor nonamer optimized for precise CD8+ T-cell activation and TCR profiling in HLA-A*03:01- and HLA-A*11:01-positive cohorts.Extensively Validated Benchmark: Backed by 18 peer-reviewed publications and validated across 23 T-cell assays and 2 MHC ligand binding studies worldwide.Core Lytic Control Component: Included as a key reference constituent in peptides&elephants' EBV Control Peptide Pool, CEF (Classic) Peptide Pool, and CEF (Advanced) Peptide Pool (>95% HPLC purity).ApplicationsEBV Lytic Phase Immunomonitoring: Measures functional cytotoxic CD8+ T-cell memory (IFN-gamma, TNF-alpha, CD107a) against immediate-early EBV reactivation in PBMCs.Recall Controls & Assay Standardization: Serves as a reliable positive control in ELISpot, Fluorospot, and Intracellular Cytokine Staining (ICS) assays.MHC Multimer & Tetramer Staining: Ideal reference ligand for generating HLA-A*03:01 and  HLA-A*11:01 peptide-MHC complexes to quantify virus-specific T-cell populations.

#

The EBV BRLF-1 134–142 peptide (ATIGTAMYK; epitope ID: 5002) is a well-characterized CD8+ T-cell target derived from the Replication and Transcription Activator (RTA / BRLF-1; UniProt: P03209) of Epstein-Barr Virus (EBV / Human Herpesvirus 4). As an immediate-early lytic phase protein, BRLF-1 initiates viral reactivation, making this nonamer sequence a crucial marker for tracking lytic cytotoxic T-cell memory. Featuring the amino acid sequence ATIGTAMYK, this peptide is restricted by HLA-A*11:01 and represents a structurally solved model antigen (PDB ID: 6JOZ) for dissecting peptide-MHC binding dynamics and TCR engagement.Key Features & BenefitsHLA-A*11:01 Restriction: High-affinity anchor nonamer optimized for precise CD8+ cytotoxic T-cell activation, tetramer generation, and immunomonitoring in HLA-A*11:01-positive donor cohorts.Structurally & Functionally Benchmark-Validated: Backed by over 17 peer-reviewed publications, 24 functional T-cell assays, 7 MHC ligand binding studies, and a published 3D crystal structure (PDB: 6JOZ).Core Control Component: Integrated as an essential reference constituent in peptides&elephants' EBV Control Peptide Pool (>95% HPLC), CEF (Classic) Peptide Pool (>95% HPLC), and CEF (Advanced) Peptide Pool (>95% HPLC).ApplicationsEBV Lytic Phase Immunomonitoring: Quantifies functional cytotoxic CD8+ T-cell memory (IFN-gamma, TNF-alpha, CD107a) against immediate-early viral reactivation in human PBMCs.Recall Controls & Assay Standardization: Serves as a gold-standard positive control in ELISpot, Fluorospot, and Intracellular Cytokine Staining (ICS) assays.Structural & Biophysical Research: Ideal reference ligand for HLA-A*11:01 docking studies, TCR cross-reactivity mapping, and structural biology applications.